Premium
Hand–foot syndrome after treatment with docetaxel
Author(s) -
Sivaramamoorthy Chitra,
Thientosapol Eddy S,
Tattersall Martin H
Publication year - 2009
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2009.tb02675.x
Subject(s) - medicine , docetaxel , family medicine , officer , cancer , history , archaeology
diarrhoea, vomiting, and hand and foot discomfort within about 10 days of ceasing therapy with capecitabine and starting docetaxel therapy. The palms of both hands and feet were inflamed and tender, with confluent blanching erythematous areas (Figure). Extensive desquamation occurred from Day 12 to Day 19 after admission, with return to normal skin by Day 30. Hand–foot syndrome has been reported after therapy with various antineoplastic agents, most commonly cytarabine, liposomal doxorubicin, capecitabine, 5-fluorouracil, sorafenib and sunitinib. Increased metabolism of capecitabine in the palms may contribute to the local reaction; as may the concentration of docetaxel in eccrine glands in the palms and soles. Management involves stopping therapy with the implicated drug, analgesia, and preventing superinfection.